According to the consensus on the treatment with PPC in patients with liver diseases, PPC was recommended for NAFLD patients with elevated ALT, AST, and γ-glutamyltransferase (GGT) after 3 months of basic therapy, patients with alcoholic liver disease who had recurrent abnormal liver function after basic therapy, and chronic hepatitis B patients with abnormal liver enzymes, and PPC can be used as adjuvant treatment for patients with moderate to severe drug-induced liver injury whose liver function damage continued to progress (Committee of the treatmen, 2017). The gene discussed is GPT; the disease is metabolic dysfunction-associated steatotic liver disease.